Clinical experience with intraurethral alprostadil (MUSE®) in the treatment of men with erectile dysfunction: A retrospective study

European Urology

Volumn 38, Issue 6, 2000, Pages 671-676

  Guay, André T ^a   Perez, Jesús B ^a   Velásquez, Ernesto ^a   Newton, Robert A ^a   Jacobson, Jerilynn P ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Alprostadil; Erectile dysfunction; MUSE therapy; Prostaglandin; Sexual dysfunction

Indexed keywords

PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; ERECTILE DYSFUNCTION; FOLLOW UP; GENITAL SYSTEM DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEXUAL INTERCOURSE; SEXUALITY; TITRIMETRY; TREATMENT FAILURE; URETHRA DISEASE;

EID: 0033668275     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020360     Document Type: Article

References (32)

1. Intracavernous injection therapy for male erectile dysfunction
2. Long-term results of corpus cavernosum autoinjection therapy for chronic erectile dysfunction
3. Long-term follow-up of patients receiving injection therapy for erectile dysfunction
4. Predictors of success and risk factors for attrition in the use of intracavernous injection
5. Twelve-month comparison of two treatments for erectile dysfunction: Self-injection versus external vacuum devices
6. Through the eyes of women: The sexual and psychological responses of women to their partner's treatment with self-injection or external vacuum therapy
7. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses
8. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: A clinical double-blind study
9. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections
10. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction
11. Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure
12. Quality of life effects of alprostadil therapy for erectile dysfunction
13. The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience
14. Oral, transdermal, and transurethral therapies for erectile dysfunction
15. Intraurethral prostaglandin E-2 cream: A possible alternative treatment for erectile dysfunction
16. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil
17. Treatment of men with erectile dysfunction with transurethral alprostadil
18. Characterization of patients in a medical endocrine-based center for male sexual dysfunction
19. MUSE therapy: Preliminary clinical observations
20. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting
21. Disappointing results for transurethral alprostadil in a V.A. impotence clinic
22. MUSE therapy for male sexual dysfunction in 454 consecutive patients: Subjective and objective results at initial evaluation with dose titration
23. Evaluation of the consistency of response to intra-urethral prostaglandin (MUSE) during at-home use
24. One-year study of transurethral alprostadil for erectile dysfunction: Efficacy, safety, and satisfaction
25. Psychologic factors affect erectile response to papaverine
26. Infusion pharmacocavernosometry and nocturnal penile tumescence findings in men with erectile dysfunction
27. Stress and the erectile response to intracavernosal prostaglandin E1 in men with erectile dysfunction
28. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy
29. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy
30. Oral sildenafil in the treatment of erectile dysfunction
31. Sildenafil in the treatment of erectile dysfunction
32. Postmarketing Safety of Sildenafil Citrate (Vi-agra): Viagra